R&D ARTICLES

• 3 Lessons For Building Biostatistics++ Teams In Pharma

  Based on my experience of more than two decades building biostatistics++ teams for Big Pharma, small biotech, and nonprofits, I offer the following advice for those interested in a path to business leadership and becoming a partner in drug development.

• Should My Startup Buy Or Produce The Proteins We Use?

  David Bienvenue, Ph.D., director of protein science AT Bonum Therapeutics, discusses his company’s challenge of deciding if they should build out a protein group or rely on vendors.

• New Ways To Approach Your Next Tech Transfer

  This article discusses the relatively new technological tools for technology transfer between sponsors and decentralized manufacturing sites or CDMOs, including electronic batch records (EBRs), laboratory information management systems (LIMS), automated monitoring, analytics, and process optimization tools.

• How To Overcome Headwinds In Securing Funding For Rare Disease Research

  The current landscape is challenging to navigate, but the good news is that there are new and emerging business strategies and funding models to consider.

• How To Reap The Benefits Of Female Talent And Innovation

  Women bring different perspectives, experiences and questions to the table that can significantly impact the design and direction of research, such as ensuring more women and other underrepresented groups are enrolled in clinical trials.

• Tech-Heavy Drug Discovery Yields Deep Pipeline

  The Business of Biotech caught up with Recursion Co-Founder & CEO Chris Gibson, Ph.D. on the heels of the company launching four clinical trials in just three quarters. That progress was built on a foundation of rapid, machine-enabled drug discovery.

• How AI Is Driving Innovation And De-Risking R&D

  With AI there is real progress being made in determining, early on, with a greater degree of accuracy, which molecule might be a hit, and which one won’t.

• How Portage Biotech Created A Lean, New Drug Development Model

  Dr. Ian Walters noticed that Big Pharma companies often would lament that small biotechs did not develop drugs the same way as their larger counterparts. He set out to change that.

• How A Robust R&D Pipeline Can Safeguard Innovation

  By approaching R&D only as a means to a profitable product and not as a valuable asset for the broader scientific or consumer community, companies and the industry lose out on opportunities for innovation, collaboration, and discovery.

• Fueling A Focused Drug Development Model

  Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end, and commercialization on the other.